Insights

Innovative Approach Insitro's commitment to transforming drug discovery through machine learning and high-throughput biology presents opportunities for partnerships with biotech and pharmaceutical companies seeking advanced analytics solutions or collaborative R&D ventures to accelerate their drug pipelines.

Strong Funding Base With a funding of over 600 million dollars and recent milestone payments, insitro demonstrates financial stability and growth potential, making it an attractive prospect for investment firms or service providers seeking to support a pioneering biotech enterprise with high market impact.

Market Positioning As a leader in AI-driven drug discovery with a focus on genetically targeted therapeutics, insitro offers sales opportunities for lab equipment, data analytics platforms, and AI-focused biotechnology services aligned with their cutting-edge research focus.

Strategic Collaborations Recent partnerships and investments from major players like Bristol Myers Squibb and the Canada Pension Plan Board highlight diligence in strategic collaborations, opening doors for engagement with similar organizations interested in joint ventures or licensing innovative drug development technologies.

Talent and Expertise Insitro’s emphasis on recruiting top talent in life sciences, genetics, engineering, and machine learning indicates a need for professional training services, specialized lab equipment, and software solutions tailored to biotech R&D teams aiming to enhance their technical capabilities.

insitro Tech Stack

insitro uses 8 technology products and services including AWS Batch, Agilent, Jupyter, and more. Explore insitro's tech stack below.

  • AWS Batch
    Data Management
  • Agilent
    Data Management
  • Jupyter
    File Sharing
  • ADP
    Human Resource Management System
  • UKG
    Human Resource Management System
  • LinkedIn
    Online Community Software
  • C++
    Programming Languages
  • Timesheets
    Time Tracking

Media & News

insitro's Email Address Formats

insitro uses at least 1 format(s):
insitro Email FormatsExamplePercentage
First@insitro.comJohn@insitro.com
50%
FLast@insitro.comJDoe@insitro.com
27%
First.Last@insitro.comJohn.Doe@insitro.com
18%
Last@insitro.comDoe@insitro.com
5%

Frequently Asked Questions

What is insitro's official website and social media links?

Minus sign iconPlus sign icon
insitro's official website is insitro.com and has social profiles on LinkedInCrunchbase.

What is insitro's SIC code NAICS code?

Minus sign iconPlus sign icon
insitro's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does insitro have currently?

Minus sign iconPlus sign icon
As of December 2025, insitro has approximately 267 employees across 4 continents, including North AmericaEuropeAfrica. Key team members include Cfo And Cbo: M. R.Chief Financial Officer: D. N.Chief People Officer: J. S.. Explore insitro's employee directory with LeadIQ.

What industry does insitro belong to?

Minus sign iconPlus sign icon
insitro operates in the Biotechnology Research industry.

What technology does insitro use?

Minus sign iconPlus sign icon
insitro's tech stack includes AWS BatchAgilentJupyterADPUKGLinkedInC++Timesheets.

What is insitro's email format?

Minus sign iconPlus sign icon
insitro's email format typically follows the pattern of First@insitro.com. Find more insitro email formats with LeadIQ.

How much funding has insitro raised to date?

Minus sign iconPlus sign icon
As of December 2025, insitro has raised $643M in funding. The last funding round occurred on Mar 15, 2021 for $400M.

When was insitro founded?

Minus sign iconPlus sign icon
insitro was founded in 2018.

insitro

Biotechnology ResearchCalifornia, United States201-500 Employees

insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients.

At insitro, we are rethinking the entire drug discovery process, from the perspective of machine learning, human genetics, and high-throughput, quantitative biology. Over the past five decades, we have seen the development of new medicines becoming increasingly more difficult and expensive, leaving many patients with significant unmet need. We’re embarking on a new approach to drug development – one that leverages machine learning and unique in vitro strategies for modeling disease state and designing new therapeutic interventions. We aim to eliminate key bottlenecks in traditional drug discovery, so we can help more people sooner and at a much lower cost to the patient and the healthcare industry.
 
We believe that by harnessing the power of technology to interrogate and measure human biology, we can have a major impact on many diseases. We invest heavily in cutting edge bioengineering technologies to enable the construction of large-scale, high-quality data sets that are designed specifically to drive machine learning methods. Our first application is to use human genetics, functional genomics, and machine learning to build a new generation of in vitro human cell-derived disease models whose response to perturbation is designed to be predictive of human clinical outcomes. 
 
This cannot be done without great people. We are bringing together an outstanding team of people whose expertise spans multiple disciplines - life sciences, machine learning, human genetics, engineering, and drug discovery - and building a unique culture where people from diverse backgrounds work as a single team towards a common goal. We offer opportunities to collaborative people with expertise in life science and computational science. Join us to help bring better health to more people, faster and cheaper.

Section iconCompany Overview

SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2018
Employees
201-500

Section iconFunding & Financials

  • $643M

    insitro has raised a total of $643M of funding over 3 rounds. Their latest funding round was raised on Mar 15, 2021 in the amount of $400Mas a Series C.

  • $100M$250M

    insitro's revenue is estimated to be in the range of $100M$250M

Section iconFunding & Financials

  • $643M

    insitro has raised a total of $643M of funding over 3 rounds. Their latest funding round was raised on Mar 15, 2021 in the amount of $400Mas a Series C.

  • $100M$250M

    insitro's revenue is estimated to be in the range of $100M$250M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.